Literature DB >> 15315756

AID is required for c-myc/IgH chromosome translocations in vivo.

Almudena R Ramiro1, Mila Jankovic, Thomas Eisenreich, Simone Difilippantonio, Selina Chen-Kiang, Masamichi Muramatsu, Tasuku Honjo, André Nussenzweig, Michel C Nussenzweig.   

Abstract

Chromosome translocations between c-myc and immunoglobulin (Ig) are associated with Burkitt's lymphoma in humans and with pristane- and IL6-induced plasmacytomas in mice. These translocations frequently involve Ig switch regions, suggesting that they might be the result of aberrant Ig class switch recombination (CSR). However, a direct link between CSR and chromosome translocations has not been established. We have examined c-myc/IgH translocations in IL6 transgenic mice that are mutant for activation induced cytidine deaminase (AID), the enzyme that initiates CSR. Here we report that AID is essential for the c-myc/IgH chromosome translocations induced by IL6.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315756     DOI: 10.1016/j.cell.2004.08.006

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  214 in total

1.  Genetic reporter system for oncogenic Igh-Myc translocations in mice.

Authors:  M Takizawa; J S Kim; L Tessarollo; N McNeil; T J Waldschmidt; R Casellas; T Ried; S Janz
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

2.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

3.  TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.

Authors:  Zhangguo Chen; Alexandra Krinsky; Rachel A Woolaver; Xiaoguang Wang; Samantha M Y Chen; Vince Popolizio; Ping Xie; Jing H Wang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

4.  Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation.

Authors:  Maki Kobayashi; Zahra Sabouri; Somayeh Sabouri; Yoko Kitawaki; Yves Pommier; Takaya Abe; Hiroshi Kiyonari; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-11       Impact factor: 11.205

Review 5.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

Review 6.  Origin of chromosomal translocations in lymphoid cancer.

Authors:  André Nussenzweig; Michel C Nussenzweig
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

7.  Chromosomal location targets different MYC family gene members for oncogenic translocations.

Authors:  Monica Gostissa; Sheila Ranganath; Julia M Bianco; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

8.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

9.  AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.

Authors:  Davide F Robbiani; Anne Bothmer; Elsa Callen; Bernardo Reina-San-Martin; Yair Dorsett; Simone Difilippantonio; Daniel J Bolland; Hua Tang Chen; Anne E Corcoran; André Nussenzweig; Michel C Nussenzweig
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

10.  Specific recruitment of protein kinase A to the immunoglobulin locus regulates class-switch recombination.

Authors:  Bao Q Vuong; Mieun Lee; Shaheen Kabir; Cristina Irimia; Stephania Macchiarulo; G Stanley McKnight; Jayanta Chaudhuri
Journal:  Nat Immunol       Date:  2009-02-22       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.